Osaic Holdings Inc. Has $6.31 Million Position in IDEXX Laboratories, Inc. $IDXX

Osaic Holdings Inc. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,458 shares of the company’s stock after acquiring an additional 1,710 shares during the quarter. Osaic Holdings Inc.’s holdings in IDEXX Laboratories were worth $6,312,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Arkadios Wealth Advisors purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $405,000. Orion Porfolio Solutions LLC raised its stake in IDEXX Laboratories by 116.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after acquiring an additional 5,770 shares during the period. Plato Investment Management Ltd lifted its holdings in IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after purchasing an additional 835 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new position in IDEXX Laboratories during the second quarter worth about $415,000. Finally, Genesis Wealth Advisors LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $215,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 29th. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Monday, December 15th. UBS Group increased their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $702.12 on Tuesday. The stock has a market cap of $56.06 billion, a price-to-earnings ratio of 55.68, a PEG ratio of 4.18 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The business has a 50-day simple moving average of $691.74 and a 200 day simple moving average of $628.25. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company posted $2.80 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.